Valeant/GSK Potiga Wins Advisory Committee Endorsement—With Assist from Wellpoint Data Plan (8/23/2010)
GSK relied on a strong post-marketing safety plan to help win a strong approval recommendation for Potiga, despite a clear signal of risk. One piece of the plan is an observational study using WellPoint’s claims data. Those arrangements will only be more common in the era of REMS.

The December 2009 OMOP Quarterly Newsletter is now available at omop.fnih.org (1/21/2010)
The Observational Medical Outcomes Partnership has released their December 2009 Newsletter. Topics include, among other things, a review of the 2009 OMOP Symposium held Nov. 12, 2009 in Bethesda, a description of the Observational Analysis Methods Research Project, and an interview with OMOP Advisory Board Member Dr. David Page from the University of Wisconsin-Madison. ProSanos is an active partner in the Observational Analysis Methods Research Project.

ProSanos featured in Insight Pharma Reports: Data Mining in Drug Development and Translational Medicine (10/16/2009)
The biopharmaceutical industry is grappling not only with sheer data volume but with the ability of researchers to extract information through identification and contextual analysis of those data that are relevant to a particular set of investigations. This report examines techniques, technology, and software used in life science data mining; data mining for early preclinical safety assessments; fata mining in clinical trials; data mining in pharmacovigilance; and business models and solutions in drug development bioinformatics.

OMOP Releases Medical Data Simulator developed by ProSanos (9/23/2009)
The Observational Medical Dataset Simulator (OSIM) is an open-source software application that allows users to create simulated datasets that conform to the OMOP Common Data Model. The procedure is being used to create simulated datasets to support OMOP's central methods development activities, as well as to facilitate the OMOP Cup methods competition.

Safety Works at GlaxoSmithKline (7/20/2009)
Best Practices Winner: GlaxoSmithKline
Project: SÆfetyWorks^®
Category: Translational and Personalized Medicine
Nominated by: ProSanos Corp.

Drug efficacy tests using EMRs may produce outcomes similar to randomized trials, study indicates (2/10/2009)
UPI (2/11) reports, "U.S. researchers predict national electronic medical records [EMRs] could test drug efficacy on a par with randomized trials," according to a study published in BMJ. For the study, researchers "examined outcomes measured by six previously performed randomized trials and the incidence of stroke, heart attack or death in a group of eight million patients." They found that "there was no difference between database outcomes" using biostatistical methods, and randomized clinical trials in nine out of 17 outcomes," after adjusting "for differences in the database's treated and untreated groups." Still, they caution that "at least 10 years of national data in the United States would be needed before electronic medical record databases could be used to measure treatment efficacy."

Summary of Testimony of Caroline J Loew, Ph.D., PhRMA (5/7/2007)
Assessing the Safety of our Nation's Drug Supply Hearing before the Subcommittee on Health, Committee on Energy and Commerce, United States House of Representatives

Keeping Approvals on Track (8/1/2005)
Applied Clinical Trials Article (August 1,2005)
Registries could strengthen the postapproval safety net—critical in the current cautious environment.

Executive Profile: Jonathan Morris (3/21/2005)
San Diego Business Journal (March 21, 2005)
Jonathan Morris’ background as a trauma surgeon probably prepared him well for the many struggles as chief executive officer of Prosanos Corp.

Highlighting ProSanos Product Development (11/30/2004)
BIO WATCH (November 30, 2004)
A profile of ProSanos and its Harrisburg operation in the newsletter of Pennsylvania BIO, which covers Pennsylvania's bioscience industry.

Patient Registries: Observations of the Real World (8/1/2004)
PharmaVOICE (August, 2004)
ProSanos CEO Jonathan Morris is featured in this article about the value of registries to pharmaceutical companies. (1MB PDF)

Incubator Grad Grows (7/16/2004)
Central Penn Business Journal (July 16, 2004)
An article describes the growth of ProSanos and the Harrisburg development office. (PDF)

Group Seeks Standards for Handling Data (5/12/2004)
San Diego Union-Tribune (May 12, 2004)
A story about the establishment of the Life Sciences-Information Technology Global Institute; ProSanos is one of the founding members.

People to Watch: Jonathan Morris, MD (4/22/2003)
San Diego Union-Tribune (April 22, 2003)
A profile of ProSanos CEO Jon Morris.

Deciphering Complexity Within Simplicity (3/26/2003)
Bio-IT World (May 26, 2003)
An interview with ProSanos Board member Michael Liebman

Breaking Informatics Barriers (10/19/2002)
Bio-IT World (October 9, 2002)
An article declaring that “vast quantities of new data types need to be combined and analyzed now,” and featuring an interview with Michael Liebman, ProSanos Board member.

Assessing the Risk of Working in a Small Genomics Shop (8/28/2002)
Genome Technology (August 2002)
Jon Morris, President and CEO of ProSanos, is featured in an article about the pros and cons of life in a dynamic startup.

Morris Moves from Healthcare to Health (6/1/2001)
Genome Technology (June 2001)
An interview with Jon Morris, President and CEO of ProSanos (requires Acrobat Reader).

A "Dream Team" Designs a Drug Discovery Computer (5/1/2001)
Genome Technology (May 2001)
Jon Morris discusses high performance computing with other industry leaders (ProSanos is referred to by its original name, GenMatics). 115 KB - requires Acrobat Reader.